EP 1228092 A1 20020807 - 24 HUMAN SECRETED PROTEINS
Title (en)
24 HUMAN SECRETED PROTEINS
Title (de)
24 MENSCHLICHE, SEKRETIERTE PROTEINE
Title (fr)
24 PROTEINES HUMAINES SECRETEES
Publication
Application
Priority
- US 0030629 W 20001108
- US 16482599 P 19991112
- US 22290400 P 20000803
Abstract (en)
[origin: WO0134643A1] The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
IPC 1-7
IPC 8 full level
C12N 15/09 (2006.01); A61K 31/7088 (2006.01); A61K 38/00 (2006.01); A61K 48/00 (2006.01); A61P 1/00 (2006.01); A61P 1/02 (2006.01); A61P 1/04 (2006.01); A61P 1/16 (2006.01); A61P 3/02 (2006.01); A61P 3/10 (2006.01); A61P 5/00 (2006.01); A61P 7/00 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 9/14 (2006.01); A61P 11/00 (2006.01); A61P 11/06 (2006.01); A61P 13/00 (2006.01); A61P 15/00 (2006.01); A61P 17/00 (2006.01); A61P 17/02 (2006.01); A61P 17/06 (2006.01); A61P 19/00 (2006.01); A61P 19/02 (2006.01); A61P 19/10 (2006.01); A61P 21/00 (2006.01); A61P 25/00 (2006.01); A61P 25/02 (2006.01); A61P 25/04 (2006.01); A61P 25/08 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/20 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); A61P 25/32 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); A61P 31/04 (2006.01); A61P 31/06 (2006.01); A61P 31/08 (2006.01); A61P 31/12 (2006.01); A61P 31/14 (2006.01); A61P 31/16 (2006.01); A61P 31/18 (2006.01); A61P 31/20 (2006.01); A61P 31/22 (2006.01); A61P 33/00 (2006.01); A61P 33/02 (2006.01); A61P 33/04 (2006.01); A61P 33/06 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 37/00 (2006.01); A61P 37/02 (2006.01); A61P 39/00 (2006.01); A61P 39/02 (2006.01); A61P 43/00 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12P 21/02 (2006.01); C12Q 1/68 (2006.01)
CPC (source: EP)
A61P 1/00 (2017.12); A61P 1/02 (2017.12); A61P 1/04 (2017.12); A61P 1/16 (2017.12); A61P 3/02 (2017.12); A61P 3/10 (2017.12); A61P 5/00 (2017.12); A61P 7/00 (2017.12); A61P 9/00 (2017.12); A61P 9/10 (2017.12); A61P 9/14 (2017.12); A61P 11/00 (2017.12); A61P 11/06 (2017.12); A61P 13/00 (2017.12); A61P 15/00 (2017.12); A61P 17/00 (2017.12); A61P 17/02 (2017.12); A61P 17/06 (2017.12); A61P 19/00 (2017.12); A61P 19/02 (2017.12); A61P 19/10 (2017.12); A61P 21/00 (2017.12); A61P 25/00 (2017.12); A61P 25/02 (2017.12); A61P 25/04 (2017.12); A61P 25/08 (2017.12); A61P 25/14 (2017.12); A61P 25/16 (2017.12); A61P 25/18 (2017.12); A61P 25/20 (2017.12); A61P 25/22 (2017.12); A61P 25/24 (2017.12); A61P 25/28 (2017.12); A61P 25/30 (2017.12); A61P 25/32 (2017.12); A61P 27/02 (2017.12); A61P 29/00 (2017.12); A61P 31/04 (2017.12); A61P 31/06 (2017.12); A61P 31/08 (2017.12); A61P 31/12 (2017.12); A61P 31/14 (2017.12); A61P 31/16 (2017.12); A61P 31/18 (2017.12); A61P 31/20 (2017.12); A61P 31/22 (2017.12); A61P 33/00 (2017.12); A61P 33/02 (2017.12); A61P 33/04 (2017.12); A61P 33/06 (2017.12); A61P 35/00 (2017.12); A61P 35/02 (2017.12); A61P 37/00 (2017.12); A61P 37/02 (2017.12); A61P 39/00 (2017.12); A61P 39/02 (2017.12); A61P 43/00 (2017.12); C07K 14/47 (2013.01); A61K 38/00 (2013.01); A61K 48/00 (2013.01); Y02A 50/30 (2017.12)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0134643 A1 20010517; AU 1472801 A 20010606; CA 2390421 A1 20010517; EP 1228092 A1 20020807; EP 1228092 A4 20031112; JP 2003520032 A 20030702
DOCDB simple family (application)
US 0030629 W 20001108; AU 1472801 A 20001108; CA 2390421 A 20001108; EP 00977036 A 20001108; JP 2001537354 A 20001108